March 10, 2022– The 14 drug companies that have imposed or announced restrictions on safety-net hospital access to 340B drug pricing program discounts collectively brought in more than a half-trillion dollars in revenues in 2021. The banner year for the drugmakers occurred as hospitals reported increasing losses of 340B savings from the cuts. Last month, most drug companies … [Read more...]
New Federal 340B Order Is Major Step Toward Restoring Drug Discounts
May 19, 2021– The Health Resources & Services Administration (HRSA) has taken decisive action to put a stop to the actions of six drug companies that are denying 340B drug pricing program discounts for medications dispensed at community pharmacies. The action could lead to the end of a nearly year-long dispute pitting for-profit pharmaceutical companies against nonprofit … [Read more...]
Outcry Intensifies Over Pharma Moves Against 340B
September 10, 2020— Five major pharmaceutical companies are flouting the 340B drug pricing program statute, and others appear poised to follow suit. But a vocal group of safety-net providers and national organizations are calling on the federal government to use its authority to put a stop to those actions before patients are harmed. Beginning in late June, the drug makers … [Read more...]